Loading clinical trials...
Loading clinical trials...
Randomized, OpEn-Label, Active-ContrOl Trial of SPI-2012 (Eflapegrastim) Versus Pegfilgrastim in the Management of Chemotherapy-Induced Neutropenia in Early-Stage BReast Cancer Patients Receiving Docetaxel and Cyclophosphamide (TC) (RECOVER)
Conditions
Interventions
SPI-2012
Pegfilgrastim
+2 more
Locations
74
United States
ACRC/ Arizona Clinical Research Center Inc.
Tucson, Arizona, United States
Yuma Regional Cancer Center
Yuma, Arizona, United States
Genesis Cancer Center
Hot Springs, Arkansas, United States
NEA Baptist Clinic | Fowler Family Center for Cancer Care
Jonesboro, Arkansas, United States
Pacific Cancer Medical Center, Inc.
Anaheim, California, United States
Compassionate Care Research Group, Inc.
Fountain Valley, California, United States
Start Date
May 10, 2017
Primary Completion Date
June 8, 2018
Completion Date
May 6, 2019
Last Updated
March 2, 2022
NCT04541381
NCT05468034
NCT03137095
NCT07547774
NCT04852887
NCT06393374
Lead Sponsor
Spectrum Pharmaceuticals, Inc
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions